Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

被引：11
|
作者：
Song, Yuqin
Song, Yongping
Liu, Lihong
Zhang, Mingzhi
Li, Zhiming
Ji, Chunyan
Xu, Wei
Liu, Ting
Xu, Bing
Wang, Xin
Gao, Sujun
Zhang, Huilai
Hu, Yu
Li, Yan
Cheng, Ying
Yang, Haiyan
Cao, Junning
Zhu, Zunmin
Hu, Jianda
Zhang, Wei
Jing, Hongmei
Ding, Kaiyang
Lu, Zhengguang
Zhang, Bin
Zhao, Renbin
Xu, Zhixin
Zhu, Jun
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141781
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Pharmacokinetics, Safety, and Efficacy of Acalabrutinib in Chinese Patients with Relapsed/Refractory Mantle Cell Lymphoma and Other B-Cell Malignancies: An Open-Label, Multicenter Phase 1/2 Trial
    Zhu, Jun
    Song, Yuqin
    Li, Jianyong
    Zhou, Keshu
    Ke, Xiaoyan
    Cai, Zhen
    Zhang, Huilai
    Yao, Tingting
    Xia, Zhen
    Wang, Yiqiu
    Lai, Peiqiong
    Liu, Xiaofeng
    BLOOD, 2022, 140 : 6496 - 6497
  • [12] Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study
    Cao, Xin-Xin
    Jin, Jie
    Fu, Cheng-Cheng
    Yi, Shu-Hua
    Zhao, Wei-Li
    Sun, Zi-Min
    Yang, Wei
    Li, Deng-Ju
    Cui, Guo-Hui
    Hu, Jian-da
    Liu, Ting
    Song, Yong-Ping
    Xu, Bing
    Zhu, Zun-Min
    Xu, Wei
    Zhang, Ming-Zhi
    Tian, Ya-Min
    Zhang, Bin
    Zhao, Ren-Bin
    Zhou, Dao-Bin
    ECLINICALMEDICINE, 2022, 52
  • [13] Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.
    Fowler, Nathan Hale
    Samaniego, Felipe
    Jurczak, Wojciech
    Lech-Maranda, Ewa
    Ghosh, Nilanjan
    Patten, Piers
    Reeves, James Andrew
    Leslie, Lori Ann
    Chavez, Julio C.
    Ghia, Paolo
    Tarella, Corrado
    Burke, John M.
    Sharman, Jeff Porter
    Kolibaba, Kathryn
    O'Connor, Owen A.
    Cheah, Chan
    Miskin, Hari P.
    Sportelli, Peter
    Weiss, Michael S.
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [14] Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results
    Cao, Xinxin
    Jin, Jie
    Cheng, Fu Cheng
    Yi, Shuhua
    Zhao, Weili
    Sun, Zimin
    Yang, Wei
    Li, Dengju
    Cui, Guohui
    Hu, Jianda
    Liu, Ting
    Song, Yongping
    Xu, Bing
    Zhu, Zunmin
    Xu, Wei
    Zhang, Mingzhi
    Li, Sichen
    Wang, Weige
    Zhao, Renbin
    Zhou, Daobin
    BLOOD, 2023, 142
  • [15] Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study
    Iyer, Swaminathan P.
    Huen, Auris
    Ai, Weiyun Z.
    Jagadeesh, Deepa
    Lechowicz, Mary J.
    Okada, Craig
    Feldman, Tatyana A.
    Ghione, Paola
    Alderuccio, Juan P.
    Champion, Rebecca
    Kim, Seo-Hyun
    Mohrbacher, Ann
    Routhu, Kasi, V
    Barde, Prajak
    Nair, Ajit M.
    Haverkos, Bradley M.
    HAEMATOLOGICA, 2024, 109 (01) : 209 - 219
  • [16] Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
    Song, Yuqin
    Zhou, Keshu
    Zou, Dehui
    Zhou, Jianfeng
    Hu, Jianda
    Yang, Haiyan
    Zhang, Huilai
    Ji, Jie
    Xu, Wei
    Jin, Jie
    Lv, Fangfang
    Feng, Ru
    Gao, Sujun
    Guo, Haiyi
    Zhou, Lei
    Huang, Jane
    Novotny, William
    Kim, Pil
    Yu, Yiling
    Wu, Binghao
    Zhu, Jun
    BLOOD, 2022, 139 (21) : 3148 - 3158
  • [17] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Fisher, Richard I.
    Bernstein, Steven H.
    Kahl, Brad S.
    Djulbegovic, Benjamin
    Robertson, Michael J.
    de Vos, Sven
    Epner, Elliot
    Krishnan, Amrita
    Leonard, John P.
    Lonial, Sagar
    Stadtmauer, Edward A.
    O'Connor, Owen A.
    Shi, Hongliang
    Boral, Anthony L.
    Goy, Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4867 - 4874
  • [18] A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma
    Martin, Peter
    Goy, Andre
    Ramchandren, Radhakrishnan
    Ferrante, Lucille
    Londhe, Anil
    McGowan, Tracy
    Bartlett, Nancy L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (04) : 1027 - 1030
  • [19] Efficacy and Safety of Lenalidomide, PD-1 Monoclonal Antibodies Combined with Orelabrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Open-Label, Single-Arm, Phase II Study
    Wang, Lingling
    Huang, Yongfen
    Chen, Hui
    Xu, Hao
    Cheng, Yuexin
    Miao, Yuqing
    BLOOD, 2024, 144 : 6488 - 6489
  • [20] Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study
    Liu, Yanfei
    Song, Yuqin
    Zuo, Shubo
    Zhang, Xian
    Liu, Hui
    Wang, Jingwen
    Wang, Jingbo
    Tang, Yongjing
    Zheng, Wen
    Ying, Zhitao
    Ping, Lingyan
    Zhang, Chen
    Wu, Meng
    Zhu, Jun
    Xie, Yan
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345